199 related articles for article (PubMed ID: 33437383)
1. The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition.
Zhao L; Huang L; Zhang J; Fan J; He F; Zhao X; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Pakvasa M; Fu K; Tucker AB; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; Qi H; He TC
Am J Transl Res; 2020; 12(12):8084-8098. PubMed ID: 33437383
[TBL] [Abstract][Full Text] [Related]
2. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
3. Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemoresistance via restoring intracellular calcium ion homeostasis.
Wang C; Xu X; Zhang P; Xiong S; Yuan J; Gao X; Guan W; Wang F; Li X; Dou H; Xu G
J Nanobiotechnology; 2022 Jul; 20(1):319. PubMed ID: 35799174
[TBL] [Abstract][Full Text] [Related]
4. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Watari H; Hosaka M; Mitamura T; Moriwaki M; Ohba Y; Todo Y; Takeda M; Ebina Y; Sakuragi N
Eur J Gynaecol Oncol; 2008; 29(6):573-7. PubMed ID: 19115681
[TBL] [Abstract][Full Text] [Related]
7. Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells.
Hong X; Li S; Li W; Xie M; Wei Z; Guo H; Wei W; Zhang S
Biochem Biophys Res Commun; 2019 Jan; 508(3):986-990. PubMed ID: 30545630
[TBL] [Abstract][Full Text] [Related]
8. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
Wang F; Zhang L; Liu J; Zhang J; Xu G
Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
[TBL] [Abstract][Full Text] [Related]
9. miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.
Kim TH; Jeong JY; Park JY; Kim SW; Heo JH; Kang H; Kim G; An HJ
Oncotarget; 2017 Sep; 8(42):72788-72800. PubMed ID: 29069826
[TBL] [Abstract][Full Text] [Related]
10. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
12. Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Sánchez-Carranza JN; Díaz JF; Redondo-Horcajo M; Barasoain I; Alvarez L; Lastres P; Romero-Estrada A; Aller P; González-Maya L
Oncol Rep; 2018 Jun; 39(6):3007-3014. PubMed ID: 29693189
[TBL] [Abstract][Full Text] [Related]
13. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
[TBL] [Abstract][Full Text] [Related]
14. Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.
Pitchakarn P; Umsumarng S; Mapoung S; Ting P; Temviriyanukul P; Punfa W; Pompimon W; Limtrakul P
J Nat Med; 2017 Oct; 71(4):693-702. PubMed ID: 28639112
[TBL] [Abstract][Full Text] [Related]
15. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
Karthikeyan S; Hoti SL; Nazeer Y; Hegde HV
Oncotarget; 2016 Jul; 7(27):42353-42373. PubMed ID: 27304668
[TBL] [Abstract][Full Text] [Related]
16. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
17. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
19. circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.
Zhang S; Cheng J; Quan C; Wen H; Feng Z; Hu Q; Zhu J; Huang Y; Wu X
Mol Ther Nucleic Acids; 2020 Mar; 19():718-730. PubMed ID: 31945729
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.
Cui X; Sun Y; Shen M; Song K; Yin X; Di W; Duan Y
ACS Appl Mater Interfaces; 2018 Mar; 10(9):7821-7831. PubMed ID: 29411964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
